683 Capital Management »

Lineage Cell Therapeutics In shares owned by 683 Capital Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by 683 Capital Management from 13F filings

Historical chart of 683 Capital Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by 683 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by 683 Capital Management

Quarter filed Position value Share count Share price at filing
2023-03-31 $193k 129k 1.50
2022-12-31 $151k 129k 1.17

More positions owned by 683 Capital Management

Palantir Technologies Cl A Put Option (PLTR)
Eli Lilly & Co. (LLY)
Tesla Motors Put Option (TSLA)
Capital One Financial (COF)
Madrigal Pharmaceuticals Put Option (MDGL)
Uniqure Nv SHS (QURE)
Alnylam Pharmaceuticals Put Option (ALNY)
Carvana Cl A (CVNA)
Insmed Com Par $.01 Put Option (INSM)
Uwm Holdings Corporation Com Cl A (UWMC)
Strategy Cl A New Put Option (MSTR)
Gxo Logistics Incorporated Common Stock (GXO)
Western Digital (WDC)
Novo-nordisk A S Adr Put Option (NVO)
United Therapeutics Corporation Put Option (UTHR)

View all positions for 683 Capital Management

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
Vanguard Group
Defender Capital
Raffles Associates
Brian McDonald
Millennium Management
Geode Capital Management
BlackRock
Renaissance Technologies
Dauntless Investment Group
State Street Corporation
GSA Capital Partners
Red Crane Wealth Management
Northern Trust
Eudaimonia Asset Management

View all funds holding Lineage Cell Therapeutics In